Autopsy report · NCT00758342

Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)

“difficulty of enrolling patients”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 4 months after it had already started.
• Ran for about 1 year 10 months before it stopped.
• 37 participants enrolled.
• Results were posted on the registry 1 year 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Alcon Research

Sponsor type

Industry

Conditions

Intraocular Pressure

Interventions

Travoprost 0.004% + Brinzolamide 1.0%; Travoprost 0.004% + Tears Natural

Participants

37

Trials that died the same way

• Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer
  “Difficulty in enrolling patients” (98% match in meaning)
• Peppermint Oil for Urinary Retention
  “Difficulty enrolling patients” (95% match in meaning)
• Microcirculation in Cardiac Surgery
  “Difficulty in enrolling new patients” (89% match in meaning)
• Platelet Function With New Pediatric Oxygenator and Heparin and Non Heparin Coating in Pediatric Cardiac Surgery
  “for difficulty to enroll patients in the study” (87% match in meaning)
• Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease
  “due to the difficulty to enroll suitable patients” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.